BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20493848)

  • 21. Efficacy of continuous versus intermittent administration of nanoformulated benznidazole during the chronic phase of Trypanosoma cruzi Nicaragua infection in mice.
    Rial MS; Arrúa EC; Natale MA; Bua J; Esteva MI; Prado NG; Laucella SA; Salomon CJ; Fichera LE
    J Antimicrob Chemother; 2020 Jul; 75(7):1906-1916. PubMed ID: 32274510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).
    Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG
    Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chagas disease 101.
    Clayton J
    Nature; 2010 Jun; 465(7301):S4-5. PubMed ID: 20571553
    [No Abstract]   [Full Text] [Related]  

  • 24. Panstrongylus geniculatus and four other species of triatomine bug involved in the Trypanosoma cruzi enzootic cycle: high risk factors for Chagas' disease transmission in the Metropolitan District of Caracas, Venezuela.
    Carrasco HJ; Segovia M; Londoño JC; Ortegoza J; Rodríguez M; Martínez CE
    Parasit Vectors; 2014 Dec; 7():602. PubMed ID: 25532708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains.
    Veloso VM; Carneiro CM; Toledo MJ; Lana M; Chiari E; Tafuri WL; Bahia MT
    Mem Inst Oswaldo Cruz; 2001 Oct; 96(7):1005-11. PubMed ID: 11685270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo drug combination for the treatment of Trypanosoma cruzi infection: A multivariate approach.
    Strauss M; Rodrigues JHS; Lo Presti MS; Bazán PC; Báez AL; Paglini-Oliva P; Nakamura CV; Bustamante JM; Rivarola HW
    Exp Parasitol; 2018 Jun; 189():19-27. PubMed ID: 29726395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experimental benznidazole treatment of Trypanosoma cruzi II strains isolated from children of the Jequitinhonha Valley, Minas Gerais, Brazil, with Chagas disease.
    Oliveira-Silva JC; Machado-de-Assis GF; Oliveira MT; Paiva NC; Araújo MS; Carneiro CM; Martins-Filho OA; Martins HR; Lana Md
    Mem Inst Oswaldo Cruz; 2015 Feb; 110(1):86-94. PubMed ID: 25742267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotype diversity of Trypanosoma cruzi in small rodents and Triatoma sanguisuga from a rural area in New Orleans, Louisiana.
    Herrera CP; Licon MH; Nation CS; Jameson SB; Wesson DM
    Parasit Vectors; 2015 Feb; 8():123. PubMed ID: 25890064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Usefulness of the polymerase chain reaction for monitoring cure of mice infected with different Trypanosoma cruzi clonal genotypes following treatment with benznidazole.
    Miyamoto CT; Gomes ML; Marangon AV; de Araújo SM; Bahia MT; Martins-Filho OA; de Lana M; de Ornelas Toledo MJ
    Exp Parasitol; 2008 Sep; 120(1):45-9. PubMed ID: 18533149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
    Filardi LS; Brener Z
    Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain.
    Camandaroba EL; Reis EA; Gonçalves MS; Reis MG; Andrade SG
    Rev Soc Bras Med Trop; 2003; 36(2):201-9. PubMed ID: 12806455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dehydroepiandrosterone-sulfate (DHEA-S) and benznidazole treatments during acute infection of two different Trypanosoma cruzi strains.
    Santos CD; Loria RM; Oliveira LG; Kuehn CC; Toldo MP; Albuquerque S; do Prado JC
    Immunobiology; 2010 Dec; 215(12):980-6. PubMed ID: 20163889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease.
    Moreno M; D'ávila DA; Silva MN; Galvão LM; Macedo AM; Chiari E; Gontijo ED; Zingales B
    Mem Inst Oswaldo Cruz; 2010 Nov; 105(7):918-24. PubMed ID: 21120364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi.
    Manarin R; Lamas MC; Bottasso E; Serra E; Revelli S; Salomón CJ
    Parasitol Int; 2013 Feb; 62(1):79-81. PubMed ID: 22975280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IV.
    Gruendling AP; Massago M; Teston AP; Monteiro WM; Kaneshima EN; Araújo SM; Gomes ML; Barbosa Md; Toledo MJ
    Am J Trop Med Hyg; 2015 Jun; 92(6):1178-89. PubMed ID: 25940197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo activity of voriconazole and benznidazole combination on trypanosoma cruzi infection models.
    Gulin JEN; Eagleson MA; López-Muñoz RA; Solana ME; Altcheh J; García-Bournissen F
    Acta Trop; 2020 Nov; 211():105606. PubMed ID: 32598923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experimental study on the therapeutic action of Ro 7-1051 on infections caused by different strains of Trypanosoma cruzi].
    Andrade SG; Figueira RM
    Rev Inst Med Trop Sao Paulo; 1977; 19(5):335-41. PubMed ID: 416483
    [No Abstract]   [Full Text] [Related]  

  • 38. CD8low T cells expanded following acute Trypanosoma cruzi infection and benznidazole treatment are a relevant subset of IFN-γ producers.
    Marins-Dos-Santos A; Olivieri BP; Ferreira-Reis R; de Meis J; Silva AA; de Araújo-Jorge TC; Lannes-Vieira J; Cotta-de-Almeida V
    PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008969. PubMed ID: 33347472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pentamidine antagonizes the benznidazole's effect in vitro, and lacks of synergy in vivo: Implications about the polyamine transport as an anti-Trypanosoma cruzi target.
    Seguel V; Castro L; Reigada C; Cortes L; Díaz MV; Miranda MR; Pereira CA; Lapier M; Campos-Estrada C; Morello A; Kemmerling U; Maya JD; López-Muñoz R
    Exp Parasitol; 2016 Dec; 171():23-32. PubMed ID: 27729250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thioridazine aggravates skeletal myositis, systemic and liver inflammation in Trypanosoma cruzi-infected and benznidazole-treated mice.
    Mendonça AAS; Gonçalves-Santos E; Souza-Silva TG; González-Lozano KJ; Caldas IS; Gonçalves RV; Diniz LF; Novaes RD
    Int Immunopharmacol; 2020 Aug; 85():106611. PubMed ID: 32447223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.